Please assess the completion status of the following clinical trial:

Trial Title: Part A: Drug Interaction Study of Sofosbuvir and Antiretroviral Therapy (ART) Combinations in HIV and Hepatitis C Virus (HCV) Co-infected Patients. Part B: Efficacy and Safety of Sofosbuvir for 12 Weeks in HIV/HCV Co-infected Patients.

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1/PHASE2
- Number of Arms: 6.0

Eligibility Criteria:
Inclusion Criteria:~* Healthy according to medical history and physical examination with exception of HCV and HIV diagnoses~* Confirmation of Chronic HCV infection~* Confirmation of Chronic HIV-1 infection~* On a stable protocol approved HIV antiretroviral (ARV) regimen with undetectable HIV-RNA~* Agree to use two forms of highly effective contraception for the duration of the study and 6 months after the last dose of study medication~* Subjects must be naive to treatment for chronic HCV infection~Exclusion Criteria:~* Known or suspected cirrhosis~* History of any other clinically significant chronic liver disease~* A history consistent with decompensated liver disease.~* Use of any prohibited medications as defined by the protocol~* Pregnant or nursing female or male with pregnant female partner~* Contraindication to PEG or RBV therapy (for Part B)~* Clinically relevant drug or alcohol abuse

- Gender: ALL
- Minimum Age: 21 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Part A: SOF+EFV/FTC/TDF (Cohort 1) (Type: EXPERIMENTAL): Participants with a prestudy regimen of EFV/FTC/TDF will receive SOF+EFV/FTC/TDF FDC for 7 days, followed by EFV/FTC/TDF FDC (or EFV+FTC/TDF) for 7 days, coadministered once daily in the evening under fasting conditions.
- Part A: SOF+EFV+ZDV/3TC (Cohort 2) (Type: EXPERIMENTAL): Participants with a prestudy regimen of EFV+ZDV/3TC will receive SOF+EFV+ZDV/3TC for 7 days followed by EFV+ZDV/3TC for 7 days. Sofosbuvir and EFV will be administered once daily in the evening under fasting conditions; ZDV/3TC will be administered twice daily, in the morning without regard to food and in the evening on an empty stomach.
- Part A: SOF+RTV+ATV+FTC/TDF (Cohort 3) (Type: EXPERIMENTAL): Participants with a prestudy regimen of RTV+ATV+FTC/TDF will receive SOF+RTV+ATV+FTC/TDF for 7 days followed by RTV+ATV+FTC/TDF for 7 days coadministered once daily in the morning with food.
- Part A: SOF+RTV+DRV+FTC/TDF (Cohort 4) (Type: EXPERIMENTAL): Participants with a prestudy regimen of RTV+DRV+FTC/TDF will receive SOF+RTV+DRV+FTC/TDF for 7 days followed by RTV+DRV+FTC/TDF for 7 days coadministered once daily in the morning with food.
- Part A: SOF+RAL+FTC/TDF (Cohort 5) (Type: EXPERIMENTAL): Participants with a prestudy regimen of RAL+FTC/TDF will receive SOF+RAL+FTC/TDF for 7 days followed by RAL+FTC/TDF for 7 days. Sofosbuvir and FTC/TDF will be administered once daily in the morning with food; RAL will be administered twice daily, in the morning with food and in the evening without regard to food.
- Part B: SOF+PEG+RBV (Type: EXPERIMENTAL): Participants will receive SOF+PEG+RBV for 12 weeks.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete